Variation of Breast Cancer Risk Among BRCA1/2 Carriers

Overview

Journal JAMA

Publisher American Medical Association

Specialty General Medicine

Date 2008 Jan 10

PMID 18182601

Citations 135

Authors

Colin B Begg

Robert W Haile

Ake Borg

Kathleen E Malone

Patrick Concannon

Duncan C Thomas

Bryan Langholz

Leslie Bernstein

Jorgen H Olsen

Charles F Lynch

Hoda Anton-Culver

Marinela Capanu

Xiaolin Liang

Amanda J Hummer

Cami Sima

Jonine L Bernstein

Affiliations

Soon will be listed here.

Abstract

Context: The risk of breast cancer in BRCA1 and BRCA2 mutation carriers has been examined in many studies, but relatively little attention has been paid to the degree to which the risk may vary among carriers.

Objectives: To determine the extent to which risks for BRCA1 and BRCA2 carriers vary with respect to observable and unobservable characteristics.

Design, Setting, And Participants: Probands were identified from a population-based, case-control study (Women's Environmental Cancer and Radiation Epidemiology [WECARE]) of asynchronous contralateral breast cancer conducted during the period of January 2000 to July 2004. Participants previously diagnosed with contralateral breast cancer or unilateral breast cancer were genotyped for mutations in BRCA1 and BRCA2. All participants had their initial breast cancer diagnosed during the period of January 1985 to December 2000, before the age of 55 years.

Main Outcome Measure: Incidence of breast cancer in first-degree female relatives of the probands was examined and compared on the basis of proband characteristics and on the basis of variation between families.

Results: Among the 1394 participants with unilateral breast cancer, 73 (5.2%) were identified as carriers of deleterious mutations (42 with BRCA1 and 31 with BRCA2). Among the 704 participants with contralateral breast cancer, 108 (15.3%) were identified as carriers of deleterious mutations (67 with BRCA1 and 41 with BRCA2). Among relatives of carriers, risk was significantly associated with younger age at diagnosis in the proband (P = .04), and there was a trend toward higher risk for relatives of contralateral breast cancer vs unilateral breast cancer participants (odds ratio, 1.4 [95% confidence interval, 0.8-2.4]; P = .28). In addition, there were significant differences in risk between carrier families after adjusting for these observed characteristics.

Conclusion: There exists broad variation in breast cancer risk among carriers of BRCA1 and BRCA2 mutations.

Citing Articles

The Association Between Breast Cancer Predisposing Genetic Variants and Multifocal, Multicentric Breast Cancer.

Vasigh M, Mohamed A, Jacobs L, Lange J, Camp M, Sun B Ann Surg Oncol. 2024; 31(13):8891-8899.

PMID: 39331289 DOI: 10.1245/s10434-024-16243-3.

Pathologic complete response after neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers.

Myers S, Sevilimedu V, Barrio A, Tadros A, Mamtani A, Robson M NPJ Breast Cancer. 2024; 10(1):63.

PMID: 39060255 PMC: 11282097. DOI: 10.1038/s41523-024-00674-y.

RBP7 functions as a tumor suppressor in HR + breast cancer by inhibiting the AKT/SREBP1 pathway and reducing fatty acid.

Yu Y, Xu Z, Zhou H, Xu R, Xu J, Liu W Cancer Cell Int. 2024; 24(1):118.

PMID: 38553715 PMC: 10979609. DOI: 10.1186/s12935-024-03299-0.

Prophylactic Salpingo-Oophorectomy and Survival After BRCA1/2 Breast Cancer Resection.

Martelli G, Barretta F, Vernieri C, Folli S, Pruneri G, Segattini S JAMA Surg. 2023; 158(12):1275-1284.

PMID: 37792368 PMC: 10551816. DOI: 10.1001/jamasurg.2023.4770.

-specific machine learning model predicts variant pathogenicity with high accuracy.

Khandakji M, Habish H, Abdulla N, Kusasi S, Abdou N, Al-Mulla H Physiol Genomics. 2023; 55(8):315-323.

PMID: 37335020 PMC: 10393322. DOI: 10.1152/physiolgenomics.00033.2023.

References

Cullinane C, Lubinski J, Neuhausen S, Ghadirian P, Lynch H, Isaacs C . Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. Int J Cancer. 2005; 117(6):988-91. DOI: 10.1002/ijc.21273. View

Mitchell G, Antoniou A, Warren R, Peock S, Brown J, Davies R . Mammographic density and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Res. 2006; 66(3):1866-72. DOI: 10.1158/0008-5472.CAN-05-3368. View

Andrieu N, Goldgar D, Easton D, Rookus M, Brohet R, Antoniou A . Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). J Natl Cancer Inst. 2006; 98(8):535-44. PMC: 2094011. DOI: 10.1093/jnci/djj132. View

Ponder B, Antoniou A, Dunning A, Easton D, Pharoah P . Polygenic inherited predisposition to breast cancer. Cold Spring Harb Symp Quant Biol. 2006; 70:35-41. DOI: 10.1101/sqb.2005.70.029. View

Antoniou A, Easton D . Models of genetic susceptibility to breast cancer. Oncogene. 2006; 25(43):5898-905. DOI: 10.1038/sj.onc.1209879. View

Ahmed M, Rahman N . ATM and breast cancer susceptibility. Oncogene. 2006; 25(43):5906-11. DOI: 10.1038/sj.onc.1209873. View

Risch H, McLaughlin J, Cole D, Rosen B, Bradley L, Fan I . Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst. 2006; 98(23):1694-706. DOI: 10.1093/jnci/djj465. View

Antoniou A, Pharoah P, McMullan G, Day N, Stratton M, Peto J . A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer. 2002; 86(1):76-83. PMC: 2746531. DOI: 10.1038/sj.bjc.6600008. View

Langholz B, Ziogas A, Thomas D, Faucett C, Huberman M, Goldstein L . Ascertainment bias in rate ratio estimation from case-sibling control studies of variable age-at-onset diseases. Biometrics. 2001; 55(4):1129-36. DOI: 10.1111/j.0006-341x.1999.01129.x. View

10.

Chatterjee N, Wacholder S . A marginal likelihood approach for estimating penetrance from kin-cohort designs. Biometrics. 2001; 57(1):245-52. DOI: 10.1111/j.0006-341x.2001.00245.x. View

11.

Risch H, McLaughlin J, Cole D, Rosen B, Bradley L, Kwan E . Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001; 68(3):700-10. PMC: 1274482. DOI: 10.1086/318787. View

12.

. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group. Br J Cancer. 2000; 83(10):1301-8. PMC: 2408797. DOI: 10.1054/bjoc.2000.1407. View

13.

Cui J, Hopper J . Why are the majority of hereditary cases of early-onset breast cancer sporadic? A simulation study. Cancer Epidemiol Biomarkers Prev. 2000; 9(8):805-12. View

14.

Antoniou A, Gayther S, Stratton J, Ponder B, Easton D . Risk models for familial ovarian and breast cancer. Genet Epidemiol. 2000; 18(2):173-90. DOI: 10.1002/(SICI)1098-2272(200002)18:2<173::AID-GEPI6>3.0.CO;2-R. View

15.

Gong G, Whittemore A . Optimal designs for estimating penetrance of rare mutations of a disease-susceptibility gene. Genet Epidemiol. 2003; 24(3):173-80. DOI: 10.1002/gepi.10219. View

16.

Easton D, Pooley K, Dunning A, Pharoah P, Thompson D, Ballinger D . Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007; 447(7148):1087-93. PMC: 2714974. DOI: 10.1038/nature05887. View

17.

Hunter D, Kraft P, Jacobs K, Cox D, Yeager M, Hankinson S . A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet. 2007; 39(7):870-4. PMC: 3493132. DOI: 10.1038/ng2075. View

18.

Chen S, Parmigiani G . Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007; 25(11):1329-33. PMC: 2267287. DOI: 10.1200/JCO.2006.09.1066. View

19.

Antoniou A, Shenton A, Maher E, Watson E, Woodward E, Lalloo F . Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 2006; 8(6):R72. PMC: 1797022. DOI: 10.1186/bcr1630. View

20.

Thompson D, Easton D . Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol Biomarkers Prev. 2002; 11(4):329-36. View